Highly Sensitive Detection of Complicated Mutations of Drug Resistance in <i>Mycobacterium tuberculosis</i> Using a Simple, Accurate, Rapid, and Low‐Cost Tailored‐Design Competitive Wild‐Type Blocking Assay
Mengqiu Yan, Zhenzhen Zhao, Tom Wu, Tangyuheng Liu, Gaolian Xu, Hong Xu, Binwu Ying
Small Methods · 2023-01
Abstract
Establishing simple, rapid, and highly sensitive molecular assays is crucial for timely diagnosis and effective treatment of drug-resistant tuberculosis. However, current genotypic drug susceptibility testing (DST) still encounters enormous challenges including lower sensitivity than phenotypic DST and insufficient accuracy. Herein, a simple, low-cost, multiplex real-time polymerase chain reaction-based assay is established to achieve highly sensitive detection of low-abundant mutants through competitive wild-type blocking (COWTB). Analytical performance of the COWTB assay can achieve 1% or even 0.1% mutants under background of 10 000 wild-type genomes/test. Furthermore, clinical practice feasibility is evaluated to identify resistance to rifampicin (RIF), isoniazid (INH), and streptomycin (SM) on 92 actual clinical samples, its sensitivity is 93.8% for RIF and 100% for INH and SM, and specificity is 100% each for RIF, INH, and SM when using DNA sequencing as the reference standard. In comparison, the sensitivity of reverse dot blotting assay commonly used in clinics is 93.8%, 90.0%, and 84.6%, and the specificity is 96.1%, 98.6%, and 100% for RIF, INH, and SM, respectively. Importantly, the COWTB assay can also be applicable for other drug-resistant mutations and pave a promising detection strategy to fill the gap between phenotypic and genotypic DST for detecting low-abundant drug-resistant M. tuberculosis.
MeSH terms
- Rifampicin
- Mycobacterium tuberculosis
- Isoniazid
- Multiplex
- Drug resistance
- Genotype
- Tuberculosis
- Multiplex polymerase chain reaction
- Polymerase chain reaction
- Biology
- Virology
- Assay sensitivity
- Wild type
- Mutant
- Streptomycin
- Drug